Advanced systemic mastocytosis (AdvSM) · line 1 · Avapritinib monotherapy (advanced systemic mastocytosis, 1L; KIT D816V+)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-AVAPRITINIB-ADVSM-1L |
| ID | IND-ADVSM-1L-AVAPRITINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-MASTOCYTOSIS |
| Sources | SRC-ESMO-AML-2020 SRC-NCCN-SM-2025 |
Notes
Preferred 1L for the ~95% of advanced SM that is KIT D816V+. Indolent SM (ISM) does NOT receive avapritinib at this dose for disease modification — avapritinib 25 mg in moderate-severe symptomatic ISM (PIONEER) is a separate, narrower symptomatic- control indication not authored here.
Used By
Algorithms
ALGO-ADVSM-1L- ALGO-ADVSM-1L